Fennec Pharmaceuticals Inc. has announced a non-brokered private offering of its common shares in Canada at a price of US$7.50 per share, targeting aggregate gross proceeds of up to US$5,025,000. The offering will be made solely to certain existing institutional shareholders in Canada, excluding Quebec, and is expected to close on November 17, 2025, pending subscription agreements and customary closing conditions, including approval from the Toronto Stock Exchange. The shares issued will not be subject to a hold period under Canadian securities laws, and the company may register them under the U.S. Securities Act of 1933. There is no assurance that the offering will be completed or that the targeted proceeds will be raised.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575845-en) on November 14, 2025, and is solely responsible for the information contained therein.